This brand name is authorized in Canada, United States
The drug CYTOGAM contains one active pharmaceutical ingredient (API):
1
Cytomegalovirus immunoglobulin
UNII 129L90A25N - HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN
|
Cytomegalovirus immunoglobulin is used as a CMV-specific polyclonal immunoglobulin preparation that binds to CMV surface antigens thereby neutralizing the potential of CMV from entering host cells and presenting the CMV particle for phagocytosis. Furthermore, cytomegalovirus immunoglobulin can activate CMV-reactive immune cells for long-lasting CMV-specific immune responses. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
CYTOGAM Solution for infusion | FDA, National Drug Code (US) | MPI, US: SPL/Old |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
J06BB09 | Cytomegalovirus immunoglobulin | J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: CA | Health Products and Food Branch | Identifier(s): 02231962 |
Country: US | FDA, National Drug Code | Identifier(s): 44206-532 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.